Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme

Biochemistry

Volumn 47, Issue 48, 2008, Pages 12822-12834

  Malito, Enrico ^a   Ralat, Luis A ^a   Manolopoulou, Marika ^a   Tsay, Julie L ^b   Wadlington, Natasha L ^c   Tang, Wei Jen ^a,b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b The University of Chicago   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; BINDING SITES; CRYSTAL STRUCTURE; ENZYMES; HORMONES; HYDROGEN; HYDROGEN PEROXIDE; INSULIN; INTEGRODIFFERENTIAL EQUATIONS; OXIDATION; PEPTIDES; PROTEINS;

CATALYTIC CENTERS; CATALYTIC CHAMBERS; CATALYTIC SITES; DEGRADING ENZYMES; HYDROPHOBIC POCKETS; MODEL SYSTEMS; MOLECULAR BASES; NITROSYLATION; PEPTIDE SUBSTRATES; STRUCTURAL PERTURBATIONS; SUBSTRATE BINDINGS; SUBSTRATE RECOGNITIONS;

SUBSTRATES;

BRADYKININ; CYSTEINE; HYDROGEN PEROXIDE; INSULINASE; KALLIDIN; N ETHYLMALEIMIDE; PEPTIDE DERIVATIVE; S NITROSOGLUTATHIONE;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CATALYSIS; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN MODIFICATION; STRUCTURE ACTIVITY RELATION;

ALKYLATION; AMINO ACID SUBSTITUTION; CATALYTIC DOMAIN; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; CYSTEINE; ENZYME INHIBITORS; HUMANS; INSULYSIN; KALLIDIN; MALEIMIDES; MODELS, MOLECULAR; OXIDATION-REDUCTION; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SUBSTRATE SPECIFICITY; SULFHYDRYL COMPOUNDS;

EID: 57049166021     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi801192h     Document Type: Article

References (61)

1. Duckworth, W. C., Bennett, R. G., and Hamel, F. G. (1998) Insulin degradation: progress and potential. Endocr. Rev. 19, 608-624.
2. Hersh, L. B. (2006) The insulysin (insulin degrading enzyme) enigma. Cell Mol. Life Sci. 63, 2432-2434.
3. Kurochkin, I. V. (2001) Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci. 26, 421-425.
4. Malito, E., Hulse, R. E., and Tang, W. J. (2008) Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol. Life Sci. 65, 2574-2585.
5. Mirsky, I. A., and Broth-Kahn, R. H. (1949) The inactivation of insulin by tissue extracts. I. The distribution and properties of insulin inactivating extracts (insulinase). Arch. Biochem. 20, 1-9.
6. Kurochkin, I. V., and Goto, S. (1994) Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345, 33-37.
7. Selkoe, D. J. (2001) Clearing the brain's amyloid cobwebs. Neuron 32, 177-180.
8. Authier, F., Posner, B. I., and Bergeron, J. J. (1996) Insulin-degrading enzyme. Clin. Invest. Med. 19, 149-160.
9. Müller, D., Baumeister, H., Buck, F., and Richter, D. (1991) Atrial natriuretic peptide (ANP) is a high-affinity substrate for rat insulin-degrading enzyme. Eur. J. Biochem. 202, 285-292.
10. Garcia, J. V., Gehm, B. D., and Rosner, M. R. (1989) An evolutionarily conserved enzyme degrades transforming growth factor-alpha as well as insulin. J. Cell Biol. 109, 1301-1307.
11. 2+-dependent ATPase. Biochem. J. 256, 847-851.
12. Im, H., Manolopoulou, M., Malito, E., Shen, Y., Zhao, J., Neant-Fery, M., Sun, C. Y., Meredith, S. C., Sisodia, S. S., Leissring, M. A., and Tang, W. J. (2007) Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J. Biol. Chem. 282, 25453-25463.
13. Shen, Y., Joachimiak, A., Rosner, M. R., and Tang, W. J. (2006) Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 443, 870-874.
14. Becker, A. (1992) An Unusual Active Site Identified in a Family of Zinc Metalloendopeptidases. Proc. Natl. Acad. Sci. 89, 3835-3839.
15. Li, P., Kuo, W. L., Yousef, M., Rosner, M. R., and Tang, W. J. (2006) The C-terminal domain of human insulin degrading enzyme is required for dimerization and substrate recognition. Biochem. Biophys. Res. Commun. 343, 1032-1037.
16. Song, E. S., Juliano, M. A., Juliano, L., and Hersh, L. B. (2003) Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J. Biol. Chem. 278, 49789-49794.
17. Song, E. S., Juliano, M. A., Juliano, L., Fried, M. G., Wagner, S. L., and Hersh, L. B. (2004) ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety. J. Biol. Chem. 279, 54216-54220.
18. Safavi, A., Miller, B. C., Cottam, L., and Hersh, L. B. (1996) Identification of gamma-endorphin-generating enzyme as insulin-degrading enzyme. Biochemistry 35, 14318-14325.
19. Song, E. S., Daily, A., Fried, M. G., Juliano, M. A., Juliano, L., and Hersh, L. B. (2005) Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions. J. Biol. Chem. 280, 17701-17706.
20. Schachter, M. (1964) Kinins - A Group of Active Peptides. Annu. Rev. Pharmacol. 4, 281-292.
21. Skidgel, R. A., and Erdos, E. G. (2006) Histamine, bradykinin, and their antagonists, in Goodman & Gilman's the Pharmacological Basis of therapeutics (Brunton, L. L., Lazo, J. S., and Parker, K. L., Eds.) pp 629-652, McGraw-Hill Companies, New York.
22. Menke, J. G., Borkowski, J. A., Bierilo, K. K., MacNeil, T., Derrick, A. W., Schneck, K. A., Ransom, R. W., Strader, C. D., Linemeyer, D. L., and Hess, J. F. (1994) Expression cloning of a human B1 bradykinin receptor. J. Biol. Chem. 269, 21583-21586.
23. McEachern, A. E., Shelton, E. R., Bhakta, S., Obernolte, R., Bach, C., Zuppan, P., Fujisaki, J., Aldrich, R. W., and Jarnagin, K. (1991) Expression cloning of a rat B2 bradykinin receptor. Proc. Natl. Acad. Sci. U.S.A. 88, 7724-7728.
24. Marceau, F., and Regoli, D. (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat. Rev. Drug Discovery 3, 845-852.
25. Yang, H. Y., and Erdös, E. G. (1967) Second kininase in human blood plasma. Nature 215, 1402-1403.
26. Deddish, P. A., Marcic, B. M., Tan, F., Jackman, H. L., Chen, Z., and Erdos, E. G. (2002) Neprilysin Inhibitors Potentiate Effects of Bradykinin on B2 Receptor. Hypertension 39, 619-623.
27. Johnson, G. D., Stevenson, T., and Ahn, K. (1999) Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J. Biol. Chem. 274, 4053-4058.
28. Hoang, M. V., and Turner, A. J. (1997) Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem. J. 327 (1), 23-26.
29. Sanden, C., Enquist, J., Bengtson, S. H., Herwald, H., and Leeb-Lundberg, L. M. (2008) Kinin B2 receptor-mediated bradykinin internalization and metalloendopeptidase EP24.15-dependent intracellular bradykinin degradation. J. Pharmacol. Exp. Ther. 326, 24-32.
30. Bachvarov, D. R., Houle, S., Bachvarova, M., Bouthillier, J., Adam, A., and Marceau, F. (2001) Bradykinin B(2) receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. J. Pharmacol. Exp. Ther. 297, 19-26.
31. Satoh, T., and Lipton, S. A. (2007) Redox regulation of neuronal survival mediated by electrophilic compounds. Trends Neurosci. 30, 37-45.
32. Shinall, H., Song, E. S., and Hersh, L. B. (2005) Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry 44, 15345-15350.
33. Ding, L., Becker, A. B., Suzuki, A., and Roth, R. A. (1992) Comparison of the enzymatic and biochemical properties of human insulin-degrading enzyme and Escherichia coli protease III. J. Biol. Chem. 267, 2414-2420.
34. Perlman, R. K., Gehm, B. D., Kuo, W. L., and Rosner, M. R. (1993) Functional analysis of conserved residues in the active site of insulin-degrading enzyme. J. Biol. Chem. 268, 21538-21544.
35. Butterfield, D. A., Drake, J., Pocernich, C., and Castegna, A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7, 548-554.
36. Foster, M. W., Hess, D. T., and Stamler, J. S. (2006) S-nitrosylation TRiPs a calcium switch. Nat. Chem. Biol. 2, 570-571.
37. Hess, D. T., Matsumoto, A., Kim, S. O., Marshall, H. E., and Stamler, J. S. (2005) Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol. 6, 150-166.
38. Kaneki, M., Shimizu, N., Yamada, D., and Chang, K. (2007) Nitrosative stress and pathogenesis of insulin resistance. Antioxid. Redox Signal. 9, 319-329.
39. Nathan, C., Calingasan, N., Nezezon, J., Ding, A., Lucia, M. S., La Perle, K., Fuortes, M., Lin, M., Ehrt, S., Kwon, N. S., Chen, J., Vodovotz, Y., Kipiani, K., and Beal, M. F. (2005) Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J. Exp. Med. 202, 1163-1169.
40. Perreault, M., and Marette, A. (2001) Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat. Med. 7, 1138-1143.
41. Yasukawa, T., Tokunaga, E., Ota, H., Sugita, H., Martyn, J. A., and Kaneki, M. (2005) S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J. Biol. Chem. 280, 7511-7518.
42. Johnson, G. D., and Ahn, K. (2000) Development of an internally quenched fluorescent substrate selective for endothelin-converting enzyme-1. Anal. Biochem. 286, 112-118.
43. Otwinowski, Z., and Minor, W. (1997) Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 276, 307-326.
44. Collaborative Computational Project, N. (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr, Sect. D: Biol. Crystallogr. 50, 760-763.
45. McCoy, A., Grosse-Kunstleve, R., Adams, P., Winn, M., Storoni, L., and Read, R. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674.
46. Adams, P. D., Grosse-Kunstleve, R. W., Hung, L. W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., and Terwilliger, T. C. (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 58, 1948-1954.
47. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 2126-2132.
48. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) PROCHECK: a program to check the stereochemistry quality of protein structures. J. Appl. Crystallogr. 26, 283-291.
49. DeLano, W. L. (2006) The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA.
50. Leissring, M. A., Lu, A., Condron, M. M., Teplow, D. B., Stein, R. L., Farris, W., and Selkoe, D. J. (2003) Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J. Biol. Chem. 278, 37314-37320.
51. Erdös, E. G., and Skidgel, R. A. (1997) Metabolism of bradykinin by peptidases in health and disease, in The kinin system. Handbook of immunopharmacology (Farmer, S. G., Ed.) pp 111-141, Academic Press, London.
52. Neant-Fery, M., Garcia-Ordonez, R. D., Logan, T. P., Selkoe, D. J., Li, L., Reinstatler, L., and Leissring, M. A. (2008) Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proc. Natl. Acad. Sci. U.S.A. 105, 9582-9587.
53. Stamler, J., and Toone, E. J. (2002) The decomposition of thionitrites. Curr. Opin. Chem. Biol. 6, 779-785.
54. Arnelle, D. R., and Stamler, J. S. (1995) NO+, NO, and NO-donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Arch. Biochem. Biophys. 318, 279-285.
55. Gaston, B., Reilly, J., Drazen, J. M., Fackler, J., Ramdev, P., Arnelle, D., Mullins, M. E., Sugarbaker, D. J., Chee, G, and Singel, D. J. (1993) Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc. Natl. Acad. Sci. U.S.A. 90, 10957-10961.
56. Droge, W. (2002) Free radicals in the physiological control of cell function. Physiol. Rev. 82, 47-95.
57. Hanafy, K. A., Krumenacker, J. S., and Murad, F. (2001) NO, nitrotyrosine, and cyclic GMP in signal transduction. Med. Sci. Monit. 7, 801-819.
58. Leeb-Lundberg, L. M., Marceau, F., Muller-Esterl, W., Pettibone, D. J., and Zuraw, B. L. (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57, 27-77.
59. Skidgel, R. A., Stanisavljevic, S., and Erdos, E. G. (2006) Kinin-and angiotensin-converting enzyme (ACE) inhibitor-mediated nitric oxide production in endothelial cells. Biol. Chem. 387, 159-165.
60. Schreiter, E. R., Rodriguez, M. M., Weichsel, A., Montfort, W. R., and Bonaventura, J. (2007) S-nitrosylation-induced conformational change in blackfin tuna myoglobin. J. Biol. Chem. 282, 19773-19780.
61. Brünger, A. (1992) Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 355, 472-475.